- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02412124
Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers
Quality of Life Outcomes From a Peer-to-Peer Support Program for Women With Gynecologic Cancer
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To test the feasibility and acceptability of a Woman-to-Woman (W2W) program for patients with gynecologic cancer at City of Hope (COH). Address the following descriptive research questions: were patients, mentors, and patients' family caregivers satisfied with the timing, format, and content of the program? Did the program benefit patients, mentors, and patients' family caregivers?
OUTLINE:
Patients participate in the W2W program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person.
After completion of study, patients are followed up at 6 and 12 months.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- City of Hope Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- PATIENT PARTICIPANTS
- Patients with newly diagnosed or recurrent gynecologic cancer (ovarian, uterine, cervical, vaginal, vulvar) actively undergoing treatment (chemotherapy, surgery, or radiation therapy) at COH (including Duarte and South Pasadena campuses)
- English-speaking patients
- PEER MENTORS
- Peer mentors will be past gynecologic cancer patients not currently undergoing treatment for their cancer, and considered without evidence of disease
- Over age 18
- PEER MENTORS: English-speaking patients
- This study is open to patients of all races and ethnicities
Exclusion Criteria:
- PEER MENTORS:
- Major psychiatric disease
- Currently undergoing treatment for active gynecologic cancer
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Supportive care (W2W program)
Patients participate in the W2W program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person.
|
Complete W2W mentoring program
Andere namen:
Complete the FACT-G
Andere namen:
Complete the W2W Patient Survey
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in quality of life benefits for patients, as assessed by the FACT-G
Tijdsspanne: Baseline to up to 12 months
|
Changes from baseline will be tested using paired t-tests.
Data will be summarized using descriptive statistics, including means for normally distributed continuous data, medians for non-normally distributed continuous data or proportions for categorical data.
Established instruments will be scored according to standard instructions, and appropriate descriptive statistics computed.
Written comments from all open ended questions analyzed using content analysis methods.
|
Baseline to up to 12 months
|
|
Satisfaction of patients with the timing, content, and format of the program, as assessed by the W2W Patient Survey
Tijdsspanne: Up to 12 months
|
Changes from baseline will be tested using paired t-tests.
Descriptive statistics on participants' satisfaction with the timing, content, and format of the intervention will be presented through summary statistics of data from the satisfaction tools.
Data will be summarized using descriptive statistics, including means for normally distributed continuous data, medians for non-normally distributed continuous data or proportions for categorical data.
|
Up to 12 months
|
|
Satisfaction of mentors with the timing, content, and format of the program, as assessed by the W2W Volunteer/Mentor Survey
Tijdsspanne: Up to 12 months
|
Descriptive statistics on participants' satisfaction with the timing, content, and format of the intervention will be presented through summary statistics of data from the satisfaction tools.
|
Up to 12 months
|
|
Satisfaction of patients' family caregivers with the timing, content, and format of the program
Tijdsspanne: Up to 12 months
|
Changes from baseline will be tested using paired t-tests.
Descriptive statistics on participants' satisfaction with the timing, content, and format of the intervention will be presented through summary statistics of data from the satisfaction tools.
|
Up to 12 months
|
|
Benefits for patients' family caregivers after participating in the program, as assessed by the Modified Caregiver Strain Index
Tijdsspanne: Up to 12 months
|
Data will be summarized using descriptive statistics, including means for normally distributed continuous data, medians for non-normally distributed continuous data or proportions for categorical data.
Established instruments will be scored according to standard instructions, and appropriate descriptive statistics computed.
Written comments from all open ended questions analyzed using content analysis methods.
|
Up to 12 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Thanh Dellinger, MD, City of Hope Medical Center
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 14359 (Andere identificatie: City of Hope Medical Center)
- NCI-2015-00467 (Register-ID: CTRP (Clinical Trial Reporting Program))
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Baarmoederhalskanker
-
Hospices Civils de LyonWervingKwaadaardige tumoren als Chordoma, Adenoid Cystic Carcinoma en SarcoomFrankrijk
-
Sun Yat-sen UniversityWervingNasofarynxcarcinoom (NPC) | EERSTE LEIDE TRADHEID FALE NASOPHARYNGEAL CARCINOMAChina
-
CG Oncology, Inc.BeëindigdCarcinoom in Situ | Overgangscelcarcinoom | Blaaskanker | Carcinoma in situ gelijktijdig met papillaire tumorenVerenigde Staten
-
Taichung Veterans General HospitalVoltooidCardiotoxiciteit | Niet-kleincellig longcarcinoom (MeSH Term: Carcinoma, Non-Small-Cell Lung) | Geneesmiddelgerelateerde bijwerkingen en ongewenste reacties (MeSH-term) | Egfr TyrosinekinaseremmerTaiwan
-
Michael A. O'DonnellWervingBlaaskanker | Urotheelcarcinoom | BCG-niet-reagerende blaaskanker | Niet-spierinvasieve blaaskanker (NMIBC) | Carcinoma in Situ (CIS) | Hooggradige papillair blaastumoren | Ta Stadium Blaaskanker | T1 Stadium Blaaskanker | BCG-refractaire blaaskanker | Hoogrisico NMIBC | Micropapillaire Variant Urotheelcarcinoom...Verenigde Staten
-
Fondazione del Piemonte per l'OncologiaWervingBorstkanker | Eierstokkanker | Colo-rectale kanker | Melanoom (huidkanker) | Niet-kleincellig longcarcinoom (MeSH Term: Carcinoma, Non-Small-Cell Lung)Italië
Klinische onderzoeken op Supportive Care
-
Xuanwu Hospital, BeijingBioray LaboratoriesNog niet aan het wervenMultiple sclerose | Neuromyelitis Optica Spectrumstoornissen | Chronische inflammatoire demyeliniserende polyradiculoneuropathie | Myasthenia Gravis, gegeneraliseerdChina
-
The Second Hospital of Shandong UniversityActief, niet wervend
-
The Second Hospital of Shandong UniversityActief, niet wervendVeiligheid en werkzaamheid van cellulaire geneesmiddelen, objectief responspercentage van proefpersonen, enzChina
-
Zhejiang UniversityCarbiogene Therapeutics Co. Ltd.WervingGeavanceerd hepatocellulair carcinoomChina
-
Nexcella Inc.Immix Biopharma, Inc.WervingLichte keten (AL) amyloïdoseVerenigde Staten
-
Second Affiliated Hospital, School of Medicine,...WervingRecidiverend en refractair B-cellymfoomChina
-
Hebei Senlang Biotechnology Inc., Ltd.Hebei Taihe Chunyu Biotechnology Co., LtdWervingLymfoom | Multipel myeloom | Acute lymfatische leukemieChina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy,...IngetrokkenAcute lymfatische leukemie | Non-Hodgkin lymfoomVerenigde Staten
-
Chunrui LiNanjing IASO Biotechnology Co., Ltd.WervingPlasmacelleukemie | Recidiverend/refractair multipel myeloomChina
-
Southwest Hospital, ChinaOnbekendLymfoom, grote B-cel, diffuusChina